- Home
- VRCA
as 01-30-2025 1:45pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 58.0M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 464.0K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $11.41 | Next Earning Date: | 02-27-2025 |
| Revenue: | $9,210,000 | Revenue Growth: | 187.45% |
| Revenue Growth (this year): | 64.32% | Revenue Growth (next year): | 73.76% |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
GlobeNewswire
a month ago
Verrica Provides Business and Operational Update
GlobeNewswire
2 months ago
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment
GlobeNewswire
2 months ago
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
GlobeNewswire
2 months ago
Verrica Announces Pricing of $42.0 Million Public Offering
GlobeNewswire
2 months ago
Verrica Announces Proposed Public Offering
GlobeNewswire
3 months ago
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.